Home Neoplasma 2022 Neoplasma Vol.69, No.5, p.1228–1236, 2022

Journal info


6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.69, No.5, p.1228–1236, 2022

Title: Association between BRAF expression in circulating tumor cells and the clinical feature of patients with multiple myeloma
Author: Ju-Xian Tang, Jia-Hui Zhang, Ke-Bing Zhou, Wang-Ting Li, Jin-Ying Wang, Qin Li, Feng-Xia Yan, Duan Xiao

Abstract: Multiple myeloma (MM) is the most common hematological malignancy with uncontrolled proliferation of monoclonal plasma cells. Despite treatment improvements, MM remains an incurable disease for most patients. Therefore, promising molecular markers are required for MM treatment decisions. In the present study, we explored the relationship between the BRAF expression in circulating tumor cells (CTCs) and the clinical features of patients with MM. The results showed that CTCs were associated with MM staging, and the expression of BRAF was associated with different CTCs. Moreover, the BRAF gene was correlated with patients’ white blood cells, blood albumin levels, and Eastern Cooperative Oncology Group (ECOG) score. BRAF expression positively correlated with total CTCs, hybrid CTCs, and mesenchymal CTCs. Taken together, CTCs tightly correlated with the clinical stages and characteristics of MM. Our findings may provide a promising prognosis biomarker for MM treatment decisions.

Keywords: multiple myeloma; circulating tumor cells; BRAF
Published online: 11-Aug-2022
Year: 2022, Volume: 69, Issue: 5 Page From: 1228, Page To: 1236
doi:10.4149/neo_2022_220428N463
Price: 18.90 €






© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.